TCM
ZNTL icon

Tang Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Tang Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,550,000
Closed -$2.34M – 192
2025
Q3 		$2.34M Hold
1,550,000
– – 0.09% 122
2025
Q2 		$1.8M Buy
1,550,000
+50,000
+3% +$65.9K 0.09% 124
2025
Q1 		$2.38M Buy
+1,500,000
New +$3.23M 0.13% 105

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Tang Capital Management's ZNTL Position: Q4 2025 in Review

Tang Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q4 2025, closing a stake of 1,550,000 shares — an estimated $2.34M sold.

Tang Capital Management first reported a position in ZNTL in Q1 2025 and held it in 3 quarters. The position peaked at $2.38M in Q1 2025. 86 funds tracked by Wall St. Rank hold ZNTL as of Q4 2025.

  • Tang Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 1,550,000 Zentalis Pharmaceuticals shares in Q4 2025, an estimated $2.34M.
  • Tang Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Tang Capital Management's Zentalis Pharmaceuticals position peaked at $2.38M in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.